Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Admission summary score
研究概览
简要总结
Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hip fracture patients in Vestfold county, Norway
排除标准
- •Patients under 18 years
- •Terminally ill
- •Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital
- •Patients who do not consent to be included in the study
结局指标
主要结局
Admission summary score
时间窗: At hospital admission (estimated to be within 24 hours after fracture)
In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note.
Number of inappropriate drugs at discharge
时间窗: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion)
After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list).
Discharge summaries written in accordance with procedure
时间窗: At discharge (estimated five days after fracture/inclusion)
In the discharge summary, the section describing drugs should be in accordance with procedure.
Discharge summary score
时间窗: At discharge (estimated five days after fracture/inclusion)
In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program
次要结局
- Readmission(90 days after discharge)
- Death(90 days after discharge)
研究者
Ben Tore Henriksen
Clinical Pharmacist
Sykehuset i Vestfold HF
